Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 M4HLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrpT2UzNjVizszN MoLnNU01KGR? MUnEUXNQ MXXlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> M4G2PFI2PDlyM{iz
H1703 M{XYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCyMlUh|ryP M33UTVEuPCCm NXf1UnVKTE2VTx?= M3zjcoVvcGGwY3XzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25idILlZZRu\W62IIfpeIghfGGvb4jp[oVv NGjsNZMzPTR7MEO4Ny=>
HUVECs MofCR5l1d3SxeHnjbZR6KEG|c3H5 NHHsZ20yODBibl2= NIjkWGUzPCCq M3uwNIF1fGWwdXH0[ZMhfGinIHHido9o[XSrdnWg[YZn\WO2czDv[kBk[Wy7Y3;zbY4hd25iVmLJMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M1;DOFI2PDVyMUi2
APRE-19 MUDBdI9xfG:|aYOgRZN{[Xl? MUi1JO69VQ>? NWnVOpd[OjRiaB?= MofEZYJwdGm|aHXzJGZNYi2vZXTpZZRm\CCycn:td5Vzfmm4YXyvZY51cS2jcH;weI9{cXNiYXP0bZZqfHl? MmS1NlU{Ojl4MUe=
MDA-MB-231 MWPBdI9xfG:|aYOgRZN{[Xl? NYjMdHZOOcLizszNxsA> NF7ZOow1QCCq M3LPR2ROW09? MVXk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= MXeyOVMxODl|Mh?=
MCF7 MXXGeY5kfGmxbjDBd5NigQ>? MXSxNFAhdk1? NFOyR24zPCCq NH\EcmlmdGmvaX7heIV{KEV{LXnu[JVk\WRiQWLFMWx2[yCjY4Tpeol1gQ>? MUeyOVE4OjV3Nx?=
HT-29  NGLKZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe5b4cyNjYEoNM1US=> NYnyNlVMQTZiaB?= MoG5[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= MoWzNlUxOTJzMkO=
MO59K  NFzqUo9EgXSxdH;4bYNqfHliQYPzZZk> MXi1xsDPxE1? MnLyO{Bl NHTsZXVFVVOR M1rSOYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= M{jaTVI1QTV|NU[x
MO59J M1;2Z2N6fG:2b4jpZ4l1gSCDc4PhfS=> NXXCeWZVPcLizszN MYO3JIQ> MnzUSG1UVw>? M4XCcoVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MV[yOFk2OzV4MR?=
MO59K  NHLZ[IVCeG:ydH;zbZMhSXO|YYm= M2TiNlExKM7:TR?= MVOyOEBp M1r4fGROW09? NYTHepltcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NYDydI9OOjR7NUO1OlE>
MO59J MYjBdI9xfG:|aYOgRZN{[Xl? NX65epVCOTBizszN MX[yOEBp MYHEUXNQ MkTFbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv Mn3sNlQ6PTN3NkG=
HepG2 MUHGeY5kfGmxbjDBd5NigQ>? NVKxXowxOTByIH7N Mli5NE42KGh? M{fNbGROW09? MXficI9kc3NiTVGtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;u NHv3e4czPDh4M{O1NC=>
A549  Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LuclMhyrWPwrC= MWeyJIg> M1jYU5N2eHC{ZYPz[ZMheGWvZYTy[Zhm\C2rbnT1Z4VlKEGtdDDhcoQhT1ONM98yJIFkfGm4YYTpc44tKFNvcHjhd4Uh[XK{ZYP0MEBk\WyuIHHwc5B1d3OrczDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? NFfiRXIzPDh2N{i2Ny=>
A549  MVHGeY5kfGmxbjDBd5NigQ>? M3ixR|ExyqEQvH5CpC=> M{[welE3KGh? NVfsOlJCTE2VTx?= NFu5S2lud2S3bHH0[ZMhfGinIFnBWkBz\XCuaXPheIlwdiCjbnSgZ4F2e2W|IILleIVvfGmxbjDv[kBPWCCrbjD0bIUhdnWlbHX1d{4> MV2yOFgxOjFzMR?=
SK-N-LO MWfGeY5kfGmxbjDBd5NigQ>? M1\0TVExOCCwTR?= MYCwMlUhcA>? NV7xOYky\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w M{HF[FI1PjV2NkC2
HL-60 M1jLNmZ2dmO2aX;uJGF{e2G7 Ml3wNE4yyqEQvF2= NYiyZ2F3PzJiaB?= NVTCVoQ3[myxY3vzJIRie2G2aX7pZk1qdmS3Y3XkJINmdGxiZHnm[oVz\W62aXH0bY9v MkH3NlQ3ODd{N{O=
HepG2  Mn3kSpVv[3Srb36gRZN{[Xl? NEKxSnMzODBibl2= NEXPVXMxNjViaB?= NY[zWoNi[XS2ZX71ZZRmeyCIb4jPJJBpd3OyaH;yfYxifGmxbh?= NW\mRmRKOjR3M{WxPVI>
H520 M{nOT2Z2dmO2aX;uJGF{e2G7 NWTrXpJwOTEEoN88US=> NXfYcosxOSCq M{LOfmROW09? NITKd5pl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> M{XoPVI1PDR5OUO1
H1975 M2\KXmZ2dmO2aX;uJGF{e2G7 MlLqNVDDqM7:TR?= MX2xJIg> NGXXV|FFVVOR NGTUOG9l\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> NIW4N24zPDR2N{mzOS=>
MG-63 MYPBdI9xfG:|aYOgRZN{[Xl? NYS2d3JnOTBiwsXN M{XMclEzKGh? MnvZ[Y5p[W6lZYOgSHAucW6mdXPl[EBieG:ydH;zbZM> NEfXVXYzPDN3OEOwNS=>
5637 NE\5e3FCeG:ydH;zbZMhSXO|YYm= NWnmToJROTEEoN88US=> NWTyepZPPDBibXnu NEfkT2Nz\X[ncoPld{BxOjGZQV[xJIV5eHKnc4Ppc44tKEOGSzDlfJBz\XO|aX;uMEBidmRiY3XscEBqdmirYnn0bY9vKGmwZIXj[YQh[nliZoXjc4ll[W5? NF;WNXEzPDN|M{i2PC=>
HEK-293 M{\k[mZ2dmO2aX;uJGF{e2G7 MoHJNVUxdk1? MW[xOkBp NV3IfIdlTE2VTx?= M4PxcYRm[3KnYYPld{BEWlRiYXP0bZZqfHl? NXnpdZpWOjR|MkSzOlY>
SW480  NVzoUGQyTnWwY4Tpc44hSXO|YYm= NI\TcJIyPTCwTR?= NH3tWWYzOCCq MkPZSG1UVw>? NUPucYN2emWmdXPld{Bk\WyudXzhdkBi[2O3bYXsZZRqd25ib3[g{tIu[2G2ZX7pci=> M3\GdVI1OzJ2M{[2
HepG2 NIX5dopHfW6ldHnvckBCe3OjeR?= MV:xNFAhdk1? MlPrNlQhcA>? NY\OT5Nz[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= M{fiUFI1Ojl5NUGw
HCT 116  MlL0SpVv[3Srb36gRZN{[Xl? M2PrVFExOCCwTR?= NVXrdFZNOjRiaB?= MUfheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? NYrTdo0zOjR{OUe1NVA>
BEL/FU MmjSSpVv[3Srb36gRZN{[Xl? NVnrVHY1OSCvTR?= MXWyOEBp MXLk[YNz\WG|ZYOgdJJwfGWrbjDs[ZZmdHNib3[geIhmKFCLM1uvRYt1KHCjdHj3ZZk> MoDyNlQzOzJyOUm=
Huh7  NIHsfJhHfW6ldHnvckBCe3OjeR?= Mn3HN:Kh|ryP NYXJZ3ZmOSCq MnPDdoVlfWOnczD0bIUhfmm{dYOg[Y51enliaX70c{B1cGViY3XscJM> NGXLOWwzPDF6NEG5Oi=>
A-375 M2\uR2Fxd3C2b4Ppd{BCe3OjeR?= Mle1OE85KM7:TR?= NELuXYgzPCCq M2DRcoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NYLLT2tUOjRzMUOxO|M>
A-375-TS  MUDBdI9xfG:|aYOgRZN{[Xl? MYS0M|gh|ryP NHribZAzPCCq M1jscoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NGPOV40zPDFzM{G3Ny=>
Mel-HO NH7WNY1CeG:ydH;zbZMhSXO|YYm= MUe0M|gh|ryP M{W5TlI1KGh? MWLlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MY[yOFEyOzF5Mx?=
Mel-HO-TS MoHxRZBweHSxc3nzJGF{e2G7 MkLZOE85KM7:TR?= M{PH[VI1KGh? MUflcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NYHVWI1tOjRzMUOxO|M>
MeWo NUiyN4s{SXCxcITvd4l{KEG|c3H5 MXu0M|gh|ryP NUn2TFdlOjRiaB?= MUTlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li M4\nUlI1OTF|MUez
Mel-2a MoHHRZBweHSxc3nzJGF{e2G7 NUjMOnRPPC96IN88US=> MWGyOEBp M{f0RoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NWXWNoNJOjRzMUOxO|M>
MDA-MB-231 MXLGeY5kfGmxbjDBd5NigQ>? NGD2U40x6oDVNECwJI5O NVnMOVJqPCCq M4PZOJN2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{TDRlIzQTB4MkW5
MDA-MB-231 NWTXbo1xTnWwY4Tpc44hSXO|YYm= Ml3YOFAxKG6P NHnoPIQ1KGh? M2XVe4Rm[3KnYYPld{BOVVBvOTDhcoQhUUxvODDwdo91\WmwIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVyyNlkxPjJ3OR?=
Jurkat Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\kRo5rOC5{NT2xMlI2KM7:TR?= MkLkNlQwPDhiaB?= MWnEUXNQ MmLVbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NH3wU5YyQTd3N{G4OS=>
Namalwa MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGC2NIkxNjJ3LUGuNlUh|ryP MVmyOE81QCCq NUW5dWxmTE2VTx?= M124d4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLTDk[ZBmdmSnboSgcYFvdmW{ NED4Tm4yQTd3N{G4OS=>
Jurkat NUfIb3lFSXCxcITvd4l{KEG|c3H5 MVuwMlI2NTFwMkWg{txO MlTPNlQwPDhiaB?= MoXxSG1UVw>? NVn4U2NocW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MYOxPVc2PzF6NR?=
Namalwa NHvzPWFCeG:ydH;zbZMhSXO|YYm= NWnh[VlLOC5{NT2xMlI2KM7:TR?= NFHEW2szPC92ODDo NFnxZ3JFVVOR M3nhNolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NWW5TFZoOTl5NUexPFU>
K562 NHPNOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzCe2MzPCCq NFrNOYVKSzVyPUK1xtExNjF2IH7N MUWxPVY3OjN4MR?=
SW1990 NHf0No1HfW6ldHnvckBCe3OjeR?= NXmzPXhNOC5yMT2xJO69VQ>? M4f2UlEhcA>? NYHMSmhMcW6qaXLpeJMhUEFvaX7keYNm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NIHlOYwyQTR4OUCyNC=>
RT112  Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvjR|AyOMLizszN NHf0fZIzPCCq NGrHNmdFVVOR NULuTW9x\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? M2\DT|E5Pzh5OEOy
MHG-U1 M4[4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXNVDDqM7:TR?= NG[zS|AzPCCq Ml3VSG1UVw>? NFPoPYVl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? MlrONVg4QDd6M{K=
SMMC-7721 NX3LdotHSXCxcITvd4l{KEG|c3H5 MX2yNFDDqG6P NGDaXIMzPCCq MV\pcoNz\WG|ZYOgR2hZNWmwZIXj[YQh[XCxcITvd4l{ NVXhWplzOTd3NUexPVE>
SMMC-7721 M3fIeWZ2dmO2aX;uJGF{e2G7 NWn6dWF1OjBywrDuUS=> NWr4W3hWOjRiaB?= MXH1dE1z\We3bHH0[ZMh|rJzLETHWFEh\XiycnXzd4lwdg>? MVixO|U2PzF7MR?=
HeLa MnPGSpVv[3Srb36gRZN{[Xl? MW[xNFDDqG6PwrC= M36zU|EhcA>? M1v6XYFtfGW{czD0bIUhdW:{cHjvcI9ogSCxZjD0bIUhfHKjboPm[ZJzcW5icnXjfYNtcW6pIHPvcZBienSvZX70 Mn\iNVY5QTB7MUW=
MRC5VI MmnlSpVv[3Srb36gRZN{[Xl? NWLXPZpbOTJwNTDtUS=> MVSwMlUhcA>? M1fPcmROW09? NYPubZJD[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NEjyUWoyPjJ{N{O5OC=>
AT5BIVA MULGeY5kfGmxbjDBd5NigQ>? M1vlWVEzNjVibV2= NHfHOmkxNjViaB?= MYTEUXNQ NUX6bINb[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? Mm\zNVYzOjd|OUS=
M059J NGPZZllHfW6ldHnvckBCe3OjeR?= MoP4NVIvPSCvTR?= MW[wMlUhcA>? M{jCcGROW09? Ml3SZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NGnMNFAyPjJ{N{O5OC=>
HeLa NIrWNIZHfW6ldHnvckBCe3OjeR?= MkC3NVIvPSCvTR?= NXXJZpRDOC53IHi= M3jSPGROW09? MoXuZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> NWrvXlg6OTZ{MkezPVQ>
N2a MYHBdI9xfG:|aYOgRZN{[Xl? MoXXNE4yNTFyIN88US=> NIDscZEzKGh? NWnKdIRycW6mdXPld{Bl\WO{ZXHz[YQh[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NEnONoMyPTh2Mke2Oy=>
Jurkat  M{XpRWtqdmG|ZTDBd5NigQ>? NIrCUldKSzVyIH;mJFI1KG6P MV[xOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID